ATF4 and pancreatic neoplasm: Downregulation of ATF4 levels decreased the IC50 value of gemcitabine, suggesting that silencing ATF4 expression can enhance sensitivity to gemcitabine in pancreatic cancer cells (Fig. 3A, B).